Viewing Protocol Section

Home Icon Home Search Icon Search Alerts Icon Stocks Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs eRecord Icon eRecord
Main Search All Studies All Organizations Report Bug
Viewing Protocol Section

Thank You for evaluating our software.

Clinical Trials

To give you an idea of how we make custom software. We have taken all of the Clinical Trials Information from our Federal Government(https://clinicaltrials.gov/).

The JSON File Structure of the files is as follows: Full Study -> Study => Sections => Modules. You are currently viewing a Protocol Section and its Modules.

We give the table structure here to give you an idea of what you are looking at. We put the explanation to the left and the data to the right.

A Protocol Section has the following Modules.

1. Identification Module

2. Status Module

3. Sponsor Collaborators Module

4. Oversight Module

5. Description Module

6. Conditions Module

7. Design Module

8. Arms Interventions Module

9. Outcomes Module

10. Eligibility Module

11. Contacts Locations Module

12. References Module

13. IPD Sharing Statement Module

Viewing Protocol Section

Study NCT05789082
Ignite Creation Date: 2024-05-06 @ 6:48 PM
Last Modification Date: 2024-10-26 @ 2:55 PM
Study NCT ID: NCT05789082
Protocol Section: NCT05789082
Start Identification Module Data
Expand Identification Module Data
Brief Title: A Study Evaluating the Safety Activity and Pharmacokinetics of Divarasib in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation
Official Title: A Phase IbII Open-Label Multicenter Study Evaluating the Safety Activity and Pharmacokinetics of Divarasib in Combination With Other Anti-Cancer Therapies in Patients With Previously Untreated Advanced Or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation
Acronym: Krascendo 170
Organization: Hoffmann-La Roche
Organization Class: INDUSTRY
Organization Study ID: BO44426
Secondary IDs
Secondary ID Type Domain Link
2022-003048-28 EUDRACT_NUMBER None None
2023-507171-22-00 OTHER EU CT Number None
Start Status Module Data
Status Verified Date: 2024-09
Overall Status: RECRUITING
Study First Submit Date:
Study First Submit QC Date:
Last Update Submit Date:
Status:
Start Sponsor Collaborators Module Data
Investigator:
Lead Sponsor: Hoffmann-La Roche
Lead Sponsor Class: INDUSTRY
Lead Sponsor: Hoffmann-La Roche
Start Oversight Module Data
Description Module:
Study Last Update Post Date Type(Status Module):
Attachment: Upload